Brands
playR continues to be CSK’s global merchandising partner for 2024 season
Mumbai: In an exciting development, playR will once again collaborate with Chennai Super Kings for the 2024 season. As the global merchandise partner, playR offers a diverse range of merchandise including apparel, sports equipment and accessories, enabling CSK fans to showcase their unwavering support for their beloved team.
playR co-founder and iCOREts Pvt Ltd director Ravi Kukreja expressed his enthusiasm, saying, “We are thrilled to renew our collaboration with CSK. CSK boasts a massive and loyal fanbase, and through this partnership, we acknowledge and respect each and every CSK fan. We at playR are working diligently towards catering to each and every CSK fan both domestic and international. From Team-wear Jersey, Fan-wear, Cricket Gear, Fitness and accessories products playR strives to create an almost exhaustive range of products that a CSK Fan can experience as part of their daily life, year-round.”
Chennai Super Kings Cricket Ltd CEO Kasi Viswanathan said “We are delighted to have signed up playR as our Global Official Merchandise Partner. We are confident that with playR we can provide our legion of fans exciting and quality CSK merchandise that they can proudly sport.”
Established in 2021, playR is committed to inspiring creativity, confidence, and fearlessness in its customers through stylish and unique offerings. From clothing like t-shirts, jackets, and shorts to sports equipment such as bats, balls, and protective gear, playR caters to a wide range of interests. The brand prioritises building lasting relationships with customers and employees, supporting community service initiatives, providing continuous employee education, and giving back to the community. With a vision to become a global leader in lifestyle, sports, and service management, playR continues to push boundaries and deliver excellence.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
